No Data
Behind the innovent bio related trade storm: taking away nearly 18 billion in financing, leaving behind five consecutive years of losses.
①Why is the market paying so much attention to the innovent bio related trade storm? ②After years of listing, taking nearly 18 billion in financing, how is the company's performance feedback?
Innovent Bio (01801) total product revenue in the third quarter exceeded 2.3 billion yuan, up more than 40% year-on-year.
Innovent bio (01801) announced that in the third quarter of 2024, the company's total product revenue exceeded the people's...
Express News | Innovent Biologics - Q3 Total Product Revenue Exceeded RMB2.3 Bln
zheshang: Continuous realization of technological innovation upgrade driving the continuous improvement of performance expectations for innovative drugs and industry chain.
The commercialization period of innovative drugs in the industry chain, driven purely by incremental value, is entering the phase of realization. The scarce incremental prosperity of the pharmaceutical sector continues to rise, with increasing international competitiveness, and there is still room for upward valuation.
Founder Yu Dechao "skillfully integrates" 20% of the international business, innovent bio (01801) is being "bombarded" by investors.
Take over the international business of XinDa without spending money?
Daiwa: Maintains 'shareholding' rating for innovent bio (01801) with a target price of HK$66.5.
Daiwa believes that there is about 70-80% chance of innovent bio (01801) stock price rising within the next 30 days.
No Data
No Data
